Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Exports to Surpass Retail Sales (India)

This article was originally published in PharmAsia News

Executive Summary

India's pharmaceutical industry will export more than they sell domestically when fiscal 2007 numbers are added up, says the Indian Pharmaceutical Alliance (IPA). In fact IPA predicts India pharmaceutical exports will grow by 35 percent annually during the next five years, compared to 16 percent for Indian retail sales, widening this export-domestic gap even more. In the last full fiscal year, pharmaceutical exports of Indian companies totaled RS 24,600 crore, which is slightly below their domestic retail sales of RS 27,903 crore. "Export growth is driven by growing dependence on generics across the world to contain health expenditure, acceptance of Indian generic drugs, aggressive expansion of Indian companies in international markets, and entry of smaller companies into exports," commented IPA secretary general D.G. Shah. Furthermore, patent drugs sales totaling around $100 billion today will see their patents expire between now and 2012, presenting generic drug makers with even more opportunities worldwide. (Click here for more

You may also be interested in...

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

US FDA Announces Plans To Resume Domestic Inspections

Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.

Finance Watch: Poseida, Nkarta And Inventiva Are July’s First Biopharma IPOs

Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts